The process following a doctor’s prescription for medication can be complex, involving decisions by federal and provincial governments regarding drug coverage, patient costs, and conditions. Pharmaceuticals play a unique role in Canadian Medicare, as they are mostly excluded from it. Recently, the federal government allocated $32 million to Prince Edward Island for the Improving Affordable Access to Prescription Drugs program, leading to the addition of over 100 medications to the public formulary and cost reductions for Islanders.
The journey for a drug to be included in the formulary starts with Health Canada’s approval, which is followed by assessment by the Patented Medicine Prices Review Board to determine fair pricing. Subsequently, the Canada Drug Agency evaluates approved drugs for cost-effectiveness before recommendations are made to provincial formularies. The final decision on drug coverage rests with provincial governments, considering factors like unmet needs, available treatments, cost, and health benefits.
Changes in drug prices and coverage rules can occur when generic versions become available, potentially leading to the inclusion of drugs in formularies or relaxed restrictions on their use. Prince Edward Island is involved in both the federal pharmacare program and the IAAPD, which supports a broader provincial formulary and reduces patient costs. The IAAPD aims to address high deductibles and copayments in the province by lowering copayments for eligible medications to $5.
Prescription drugs were initially excluded from Canada’s universal healthcare system, which focused on hospital and physician care. The vision of adding drug coverage after hospital and physician services never fully materialized due to cost concerns. The historical context of the healthcare system’s formation sheds light on the current landscape of drug coverage in Canada.
